Jiangsu Recbio Technology Co., Ltd. Class H (HK:2179) has released an update.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Jiangsu Recbio Technology has launched a phase III clinical trial in China for its novel shingles vaccine, REC610, targeting individuals aged 40 and above. This trial aims to evaluate the vaccine’s efficacy, safety, and immunogenicity, with a significant demand for domestic alternatives to the currently available vaccine. REC610 has shown promising results in earlier trials, highlighting its potential to be a strong contender in the shingles vaccine market.
For further insights into HK:2179 stock, check out TipRanks’ Stock Analysis page.